Related Experiment Video
Updated: Feb 3, 2026

Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
Published on: June 21, 2024
Correction: Genitourinary syndrome of menopause
Anna Camille Moreno1, Sabrina K Sikka1, Holly L Thacker2,3
1Specialized Women's Health Fellow, Center for Specialized Women's Health, Women's Health Institute, Cleveland Clinic, Cleveland, OH, USA.
A correction clarifies prasterone use in breast cancer survivors. Prasterone is not contraindicated for all breast cancer patients, but caution is advised due to estrogen metabolism.
Area of Science:
- Oncology
- Gynecology
- Pharmacology
Background:
- Genitourinary syndrome of menopause (GSM) affects breast cancer survivors.
- Estrogen therapy is often contraindicated in this population.
- Prasterone is a potential treatment option for GSM.
Purpose of the Study:
- To correct misinformation regarding prasterone contraindications in breast cancer survivors.
- To provide accurate guidance on prasterone use for GSM in this patient group.
Main Methods:
- Review of existing literature and clinical guidelines.
- Correction of a previously published table regarding drug contraindications.
Main Results:
- Prasterone is not absolutely contraindicated in all breast cancer survivors.
- A warning regarding estrogen metabolism and contraindication for exogenous estrogen use is relevant.
- Prasterone has not been studied in patients with a history of breast cancer.
Conclusions:
- Accurate information on prasterone use is crucial for managing GSM in breast cancer survivors.
- Clinicians should exercise caution and consider individual patient history when prescribing prasterone.
Related Concept Videos
Menopause
Distance Corrections
Power Factor Correction
Anatomy of the Genitourinary System I: Kidneys and Ureters
Anatomy of the Genitourinary System II: Bladder and Urethra
Physiology of the Genitourinary System II: Tubular Reabsorption and Secretion

